Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Jurnal MedScientiae Jurnal MedScientiae The International Journal of Medical Science and Health Research
Elvantie
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Veterinary

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
KEPARAHAN AKNE VULGARIS DENGAN PENGGUNAAN PROBIOTIK ORAL Elvantie; Arini Astasari Widodo; Budiman Hartono
Jurnal MedScientiae Vol. 2 No. 1 (2023): April
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background. Oral probiotics are microorganisms that have various benefits based on theoretical evidence of the skin, brain, and gut. Oral probiotics are an effective choice in the management of acne vulgaris, which has been proven by studies that state that oral probiotics can reduce the degree of acne, inflammatory lesions, non-inflammatory lesions and reduce excess sebum production. Method. The research articles reviewed are in the form of analytical reviews through the PubMed and Google Scholar databases. Results. A total of 6 research articles were selected according to the purpose of writing this literature review. Conclusion. The use of oral probiotics can reduce inflammatory lesions, the degree of severity of acne vulgaris, total inflammatory lesions, and reduce excessive sebum production. Oral probiotics, in some cases, can cause side effects such as gastrointestinal disturbances in the form of bloated. Probiotics are measured in colony-forming units (CFU) which indicate the number of viable cells. The dosage concentration of each probiotic varies, but oral probiotics still provide an effective effect on the treatment of acne vulgaris.
KEPARAHAN AKNE VULGARIS DENGAN PENGGUNAAN PROBIOTIK ORAL Elvantie; Arini Astasari Widodo; Budiman Hartono
Jurnal MedScientiae Vol. 2 No. 1 (2023): April
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36452/jmedscientiae.v2i1.2797

Abstract

Background. Oral probiotics are microorganisms that have various benefits based on theoretical evidence of the skin, brain, and gut. Oral probiotics are an effective choice in the management of acne vulgaris, which has been proven by studies that state that oral probiotics can reduce the degree of acne, inflammatory lesions, non-inflammatory lesions and reduce excess sebum production. Method. The research articles reviewed are in the form of analytical reviews through the PubMed and Google Scholar databases. Results. A total of 6 research articles were selected according to the purpose of writing this literature review. Conclusion. The use of oral probiotics can reduce inflammatory lesions, the degree of severity of acne vulgaris, total inflammatory lesions, and reduce excessive sebum production. Oral probiotics, in some cases, can cause side effects such as gastrointestinal disturbances in the form of bloated. Probiotics are measured in colony-forming units (CFU) which indicate the number of viable cells. The dosage concentration of each probiotic varies, but oral probiotics still provide an effective effect on the treatment of acne vulgaris.
A Comprehensive Systematic Review of Treatment Strategies for Keloid and Hypertrophic Scar Elvantie; Virgina Maurila Palakkang; Petra Damiana Anindita
The International Journal of Medical Science and Health Research Vol. 29 No. 1 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/jr6sw150

Abstract

Introduction: Keloid and hypertrophic scars represent a significant clinical challenge due to their complex pathogenesis, propensity for recurrence, and psychosocial impact on patients. Despite numerous available interventions, there is no universally accepted gold-standard treatment, and evidence on comparative efficacy and safety remains fragmented. Methods: A systematic evidence synthesis was conducted based on a comprehensive screening of 80 studies, including randomized controlled trials, systematic reviews, and meta-analyses. Studies were selected based on predefined criteria including clinically diagnosed scars, therapeutic interventions, human studies, and quantitative outcome reporting. Data were extracted on treatment strategies, scar characteristics, patient demographics, effectiveness, safety, and study design. Results: Combination therapies consistently outperformed monotherapies. Triamcinolone acetonide (TAC) combined with 5-fluorouracil (5-FU) showed superior efficacy (77.2–93.3% response) and lower recurrence compared to TAC alone (Liu et al., 2020; Khalid et al., 2019). TAC with botulinum toxin A also ranked highly (SUCRA 82.2%) (Yang et al., 2021). Verapamil demonstrated a better safety profile but slower onset of action. Laser therapies, especially fractional CO₂ with 5-FU, showed significant scar improvement (Foppiani et al., 2024). Surgical excision with adjuvant high-dose-rate brachytherapy yielded the lowest recurrence (3.1%) (van Leeuwen et al., 2014). Discussion: The synthesis highlights the importance of multimodal, context-specific treatment strategies. Combination regimens address multiple pathological pathways, enhancing outcomes while mitigating adverse effects. Discrepancies in monotherapy efficacy are attributed to variations in protocols, concentrations, and scar characteristics. Conclusion: Combination therapy, particularly TAC+5-FU, represents the most effective and balanced approach for most keloid and hypertrophic scar cases. Treatment should be individualized based on scar type, location, size, patient skin type, and tolerance to side effects. Future research should focus on standardized protocols, long-term follow-up, and novel targeted therapies.
Co-Authors Arini Astasari Widodo Arini Astasari Widodo Budiman Hartono Budiman Hartono Petra Damiana Anindita Virgina Maurila Palakkang